Simon Pedder
Chief Executive Officer at Nirogy Therapeutics, Inc.
Profile
Simon C.
Pedder founded Chelsea Therapeutics International Ltd.
in 2005, where he worked as President, Chief Executive Officer & Director from 2005 to 2012.
Dr. Pedder also currently works at Nirogy Therapeutics, Inc., as Chief Executive Officer from 2022, Eboo Pharmaceuticals, Inc., as Director, Ballantyne Therapeutics, Inc., as Director, and Atlantic Research Group, Inc., as Director.
Dr. Pedder also formerly worked at Ivory Capital Corp., as President & Chief Executive Officer from 2004 to 2005, Chelsea Therapeutics, Inc., as President & Chief Executive Officer from 2004 to 2012, Novelos Therapeutics, Inc., as Chief Executive Officer & Director from 2013 to 2014, Cellectar Biosciences, Inc., as President, Chief Executive Officer & Director from 2014 to 2015, Oncotelic Therapeutics, Inc., as Independent Director from 2016 to 2019, Delcath Systems, Inc., as Independent Director from 2017 to 2019, Avalo Therapeutics, Inc., as President & Director in 2020, Oncology Pharma, Inc., as Vice President, Athenex, Inc., as Chief Business & Strategy Officer-Proprietary, Hoffmann-La Roche, Inc., as Vice President-Pharmaceutical Business & Oncology, Shearwater Corp., as Vice President-Drug Development from 2001 to 2002, and the University of Saskatchewan College of Medicine, as Member.
Dr. Pedder received his graduate degree from Concordia University, undergraduate degree from The University of Waterloo, and doctorate degree from the University of Saskatchewan College of Medicine.
Simon Pedder active positions
| Companies | Position | Start |
|---|---|---|
| Eboo Pharmaceuticals, Inc. | Director/Board Member | - |
Ballantyne Therapeutics, Inc.
 Ballantyne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ballantyne Therapeutics, Inc. manufactures pharmaceuticals. The private company is based in Charlotte, NC. | Director/Board Member | - |
Atlantic Research Group, Inc.
 Atlantic Research Group, Inc. Miscellaneous Commercial ServicesCommercial Services Atlantic Research Group, Inc. operates as a rare disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. It offers strategic consulting, clinical trial management services, clinic data and analytics solutions, pharmacovigilance and medical monitoring. The company was founded by Paul Bishop and Lyle Camblos in 2004 and is headquartered in Charlottesville, VA. | Director/Board Member | - |
Nirogy Therapeutics, Inc.
 Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | Chief Executive Officer | 2022-01-11 |
Former positions of Simon Pedder
| Companies | Position | End |
|---|---|---|
| ATHENEXPAR | Corporate Officer/Principal | 2021-12-30 |
| AVALO THERAPEUTICS, INC. | Chairman | 2020-04-23 |
| ONCOTELIC THERAPEUTICS, INC. | Director/Board Member | 2019-04-09 |
| DELCATH SYSTEMS, INC. | Director/Board Member | 2019-04-09 |
| CELLECTAR BIOSCIENCES, INC. | Chief Executive Officer | 2015-06-14 |
Training of Simon Pedder
| Concordia University | Graduate Degree |
| The University of Waterloo | Undergraduate Degree |
| University of Saskatchewan College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| ONCOLOGY PHARMA INC. | Health Technology |
| DELCATH SYSTEMS, INC. | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private companies | 11 |
|---|---|
| Ivory Capital Corp. | Finance |
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Shearwater Corp.
 Shearwater Corp. Pharmaceuticals: MajorHealth Technology Part of Nektar Therapeutics, Shearwater Corp. is a private company that provides research services focused on health care applications of advanced PEGylation. The company is based in Huntsville, AL. The company was founded by James R. Hudson, J. Milton Harris. Shearwater was acquired by Nektar Therapeutics on July 02, 2001 for $164.50 million. | Health Technology |
| Chelsea Therapeutics, Inc. | Health Technology |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
| Eboo Pharmaceuticals, Inc. | |
Ballantyne Therapeutics, Inc.
Ballantyne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ballantyne Therapeutics, Inc. manufactures pharmaceuticals. The private company is based in Charlotte, NC. | Health Technology |
Atlantic Research Group, Inc.
Atlantic Research Group, Inc. Miscellaneous Commercial ServicesCommercial Services Atlantic Research Group, Inc. operates as a rare disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. It offers strategic consulting, clinical trial management services, clinic data and analytics solutions, pharmacovigilance and medical monitoring. The company was founded by Paul Bishop and Lyle Camblos in 2004 and is headquartered in Charlottesville, VA. | Commercial Services |
Nirogy Therapeutics, Inc.
Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Simon Pedder
